In recent years, many advances have been made in pharmacological therapies for neoplastic and inflammatory canine neurological disorders. Both groups of diseases are now routinely treated with chemotherapeutic agents; various other medical therapies are also emerging. This Research Topic will therefore focus on chemotherapy and other pharmacological therapies for central nervous system (CNS) disorders in the dog. This includes therapy of glioma and other CNS neoplasms, as well as meningoencephalitis of unknown etiology (MUE), granulomatous meningoencephalomyelitis (GME) and necrotizing encephalitis.
The goal of this Research Topic is to address knowledge gaps in the use of chemotherapy and other medical therapies in the treatment of neoplastic and inflammatory CNS disorders in dogs.
Despite recent advances in our understanding and available treatment options, canine glioma remains a largely terminal disease. The prognosis for many other CNS neoplasms is similar. We seek manuscripts regarding chemotherapy, nanoparticles and other pharmacotherapies for all forms of canine brain tumor. The agent being studied can be delivered by either systemic or intracranial routes of administration, and if appropriate can accompany surgical or radiation therapy.
A great deal of information has recently become available regarding the treatment of MUE in dogs, however the optimal therapy remains unclear. For some pharmacologic agents, aspects such as dose, bioavailability and the route of administration need further study. We seek manuscripts addressing chemotherapeutic and other medical therapy for MUE. The use of contemporary ante-mortem diagnostic criteria (MRI, CSF and exclusion of infectious diseases) for MUE is anticipated. Studies using histology to diagnose GME, necrotizing encephalitis or other inflammatory disorders are also suitable.
We will consider prospective clinical trials, retrospective studies and pilot studies that are focused upon medical therapies for canine brain tumors or inflammatory syndromes. Manuscripts addressing chemotherapy are particularly encouraged. We are not seeking studies focused on surgery or radiation therapy, but studies in which these treatment modalities accompany the medical therapy being studied are welcome.
Specific themes to be addressed:
Treatment of canine glioma, meningioma and other CNS neoplasms with chemotherapeutic agents
All medical therapies for canine CNS neoplasia, including nanoparticles and locally administered agents
BBB disruption to increase delivery of pharmacologic agents
Treatment of MUE with chemotherapeutic agents
Outcome measures for MUE
Bioavailability of chemotherapeutic agents used for canine CNS neoplasms or inflammatory syndromes
Manuscript types solicited:
Original Research
Review
Systematic Review
Manuscript types that may be eligible for inclusion:
Mini-Review
In recent years, many advances have been made in pharmacological therapies for neoplastic and inflammatory canine neurological disorders. Both groups of diseases are now routinely treated with chemotherapeutic agents; various other medical therapies are also emerging. This Research Topic will therefore focus on chemotherapy and other pharmacological therapies for central nervous system (CNS) disorders in the dog. This includes therapy of glioma and other CNS neoplasms, as well as meningoencephalitis of unknown etiology (MUE), granulomatous meningoencephalomyelitis (GME) and necrotizing encephalitis.
The goal of this Research Topic is to address knowledge gaps in the use of chemotherapy and other medical therapies in the treatment of neoplastic and inflammatory CNS disorders in dogs.
Despite recent advances in our understanding and available treatment options, canine glioma remains a largely terminal disease. The prognosis for many other CNS neoplasms is similar. We seek manuscripts regarding chemotherapy, nanoparticles and other pharmacotherapies for all forms of canine brain tumor. The agent being studied can be delivered by either systemic or intracranial routes of administration, and if appropriate can accompany surgical or radiation therapy.
A great deal of information has recently become available regarding the treatment of MUE in dogs, however the optimal therapy remains unclear. For some pharmacologic agents, aspects such as dose, bioavailability and the route of administration need further study. We seek manuscripts addressing chemotherapeutic and other medical therapy for MUE. The use of contemporary ante-mortem diagnostic criteria (MRI, CSF and exclusion of infectious diseases) for MUE is anticipated. Studies using histology to diagnose GME, necrotizing encephalitis or other inflammatory disorders are also suitable.
We will consider prospective clinical trials, retrospective studies and pilot studies that are focused upon medical therapies for canine brain tumors or inflammatory syndromes. Manuscripts addressing chemotherapy are particularly encouraged. We are not seeking studies focused on surgery or radiation therapy, but studies in which these treatment modalities accompany the medical therapy being studied are welcome.
Specific themes to be addressed:
Treatment of canine glioma, meningioma and other CNS neoplasms with chemotherapeutic agents
All medical therapies for canine CNS neoplasia, including nanoparticles and locally administered agents
BBB disruption to increase delivery of pharmacologic agents
Treatment of MUE with chemotherapeutic agents
Outcome measures for MUE
Bioavailability of chemotherapeutic agents used for canine CNS neoplasms or inflammatory syndromes
Manuscript types solicited:
Original Research
Review
Systematic Review
Manuscript types that may be eligible for inclusion:
Mini-Review
